Hydromorphone Tablet Suppliers & Bulk Manufacturers

Available Forms: Tablets/ capsules/ Injectable / Oral Solution

Available Strengths: 2mg, 4mg, 8mg / 1 mg/mL, 2 mg/mL, 4 mg/mL

Reference Brands: Dilaudid (USA), Exalgo, Palladone(EU/UK)

Category: Pain Management

Hydromorphone is a potent semi-synthetic opioid analgesic, about 5–8 times stronger than morphine. It is used for the management of moderate to severe pain in patients requiring continuous opioid therapy. Available in tablet, extended-release, injection, and oral solution forms, hydromorphone provides effective pain relief but requires strict control due to its high potential for dependence and abuse. Hydromorphone Tablet is available in Tablets/ capsules/ Injectable / Oral Solution and strengths such as 2mg, 4mg, 8mg / 1 mg/mL, 2 mg/mL, 4 mg/mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Hydromorphone Tablet is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Hydromorphone Tablet can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Hydromorphone is a powerful opioid analgesic used for the management of moderate-to-severe acute pain as well as severe chronic pain, including cancer-related pain. It exerts its effects by binding selectively to mu-opioid receptors in the central nervous system, which alters the perception of pain and provides effective analgesia. In addition to its primary pain-relieving action, hydromorphone also acts at the medulla level, leading to cough suppression and respiratory effects, which must be carefully monitored during therapy.

Hydromorphone’s pharmacokinetic properties allow for rapid onset of action and predictable duration of effect, making it suitable for both immediate and extended-release formulations depending on patient needs. Healthcare providers should consider potential interactions with other central nervous system depressants, assess for risk of respiratory depression, and monitor for common opioid-related adverse effects such as nausea, dizziness, and constipation. Proper dosing and careful patient monitoring are essential to optimize efficacy while minimizing the risk of toxicity and dependency.

Overall, hydromorphone is a critical medication in pain management, providing reliable and potent analgesia for patients with acute or chronic pain, and is an indispensable option for clinicians seeking effective opioid therapy.